Research on GLP-1 drugs and asthma attacks looks at whether patients have fewer exacerbations. This study asked a different question. A Shanghai clinic tracked eosinophil counts in people prescribed semaglutide [1]. Clinicians use these white blood cells to help identify types of asthma and assess who may respond to certain biologic drugs.
Counts fell. The median went from 160 to 110 per microliter, the eosinophil percentage from 2.20% to 1.60%, and the proportion of people sitting below the commonly used 150 threshold rose from 44.20% to 65.79%. Reductions appeared in people who started above the threshold and in those who started below it.
The median percentage decline was 31.58% in the group with a BMI below 28 and 21.04% in the group at or above 28 (P = 0.037) [1]. In the adjusted analysis, the starting eosinophil count was the only independent predictor of the decline. The study design leaves open how much of the change came from semaglutide, weight change or other factors.